Malignant solid neoplasm, SMO-mutated or PTCH-1-mutated (Hedgehog)
Revision as of 13:05, 29 August 2022 by Warner-admin (talk | contribs) (Text replacement - "'''contains verified protocol'''" to "'''contains dosing details in manuscript'''")
1 regimens on this page
1 variants on this page
|
All lines of therapy
Vismodegib monotherapy
Regimen
| Study | Evidence |
|---|---|
| Hainsworth et al. 2018 (MyPathway) | Phase 2a |
Eligibility criteria
- SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations
Targeted therapy
- Vismodegib (Erivedge) 150 mg PO once per day
Continued indefinitely
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains dosing details in manuscript PubMed NCT02091141